Return to Results

A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy

new search

Trial Conditions
  • Breast Cancer
What is the purpose of this trial?

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production. It is not yet known whether anastrozole is more effective than tamoxifen in preventing the recurrence of breast cancer. PURPOSE: This randomized phase III trial is studying anastrozole to see how well it works compared to tamoxifen in preventing the recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ who are undergoing lumpectomy and radiation therapy.

Date & Status

Active, not recruiting

Who can Participate?


0 and older




- Histologically confirmed ductal carcinoma in situ (DCIS) of the breast

- Mixed DCIS and lobular carcinoma in situ (LCIS) allowed

- Must have undergone lumpectomy

- Margins must be histologically free of disease

- Re-excision to obtain tumor-free margins allowed

- No more than 84 days since prior lumpectomy or re-excision

- More than 1 area of DCIS allowed provided all disease is removed with tumor-free

- Masses or clusters of calcification that are clinically or mammographically
suspicious must be biopsied

- No prior invasive breast cancer or DCIS

- Patients with a history of LCIS are eligible

- No prior or concurrent invasive (including microinvasive) breast cancer

- DCIS "suspicious" for microinvasion allowed

- No bilateral malignancy

- No mass or mammographic abnormality suspicious for malignancy in the opposite
breast unless not malignant as proven by biopsy

- No Paget's disease of the nipple

- No positive ipsilateral axillary or intramammary nodes

- No palpable nodes in the ipsilateral or contralateral axilla or palpable
supraclavicular or infraclavicular nodes unless not involved with tumor as
proven by biopsy

- Hormone receptor status:

- Estrogen- or progesterone-receptor positive as determined by

- Borderline results are considered positive



- See Menopausal status


- Female

Menopausal status:

- Postmenopausal as defined by at least 1 of the following:

- Prior documented bilateral oophorectomy

- At least 12 months without spontaneous bleeding

- Age 55 or over with prior hysterectomy without oophorectomy

- Age 54 or under with prior hysterectomy without oophorectomy with a documented
follicle-stimulating hormone level in the postmenopausal range

Performance status

- Zubrod 0-2

Life expectancy

- At least 10 years (excluding diagnosis of breast cancer)


- WBC normal


- AST normal

- Bilirubin normal

- Alkaline phosphatase normal

- No hepatic disease that would preclude administration of study drugs


- Creatinine normal

- No renal disease that would preclude administration of study drugs


- No prior documented cerebral vascular accident or transient ischemic attack

- No prior deep vein thrombosis

- No cardiovascular disease that would preclude administration of study drugs

- No uncontrolled hypertension (i.e., systolic blood pressure at least 180 mm Hg or
diastolic blood pressure at least 110 mm Hg based on the average of 2 or more
readings at each of 2 or more visits after initial screening)

- No uncontrolled atrial fibrillation


- No pulmonary embolus


- Not pregnant or nursing

- Patients with a history of non-breast malignancies are eligible provided they have
been disease-free for ≥ 5 years and are deemed by their physician to be at low risk
for recurrence

- No other malignancy within the past 5 years except treated basal cell or squamous
cell skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the colon, or
melanoma in situ

- No psychiatric or addictive disorders that would preclude informed consent

- No uncontrolled diabetes, defined as hemoglobin A1C greater than 9% (fasting glucose
200 mg/dL)

- No nonmalignant systemic disease that would preclude administration of study drugs


Endocrine therapy

- No prior or concurrent aromatase inhibitors (e.g., exemestane or letrozole) or

- No concurrent raloxifene or other selective estrogen receptor modulators

- No concurrent sex hormone therapy (e.g., estrogen or progesterone replacement
therapy, oral contraceptives, androgens, luteinizing hormone releasing hormone
analogs, prolactin inhibitors, or antiandrogens)

- Low-dose estrogen vaginal creams or Estring allowed


- Radiotherapy for this cancer initiated before study is allowed


- See Disease Characteristics

- No prior or concurrent mastectomy for DCIS

- Prior sentinel node biopsy or axillary node dissection allowed provided nodes are
pathologically negative


- No concurrent warfarin

- No other systemic therapy for this cancer initiated before study

- No other concurrent anticancer therapy unless permitted by the protocol investigator

- No concurrent participation in another clinical trial of therapy for DCIS

- Concurrent participation in protocol NSABP-B-39 allowed

Gender: Female
Steward Physician(s)
  • Norman Wolmark, MD
  • Laura A. Vallow, MD
  • Kathy S. Albain, MD
  • Pat W. Whitworth, MD
  • Mary Cianfrocca, MD
  • St. Elizabeth's Medical Center - Active, not recruiting
  • Saint Anne's Hospital - Active, not recruiting
  • Holy Family Hospital - Active, not recruiting
  • Norwood Hospital - Active, not recruiting
Trial Interventions
  • anastrozole
  • tamoxifen citrate
  • Radiation Therapy
Physician Researcher

Investigator Name:

  • Norman Wolmark, MD
  • Laura A. Vallow, MD
  • Kathy S. Albain, MD
  • Pat W. Whitworth, MD
  • Mary Cianfrocca, MD

Other Information

Sponsor: NSABP Foundation Inc
Phase: Phase 3
Trial ID: NCT00053898
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions